Recruiting Epilepsy Studies in La Jolla
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy....
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no re...
About Epilepsy Clinical Trials in La Jolla
Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. It affects about 50 million people worldwide. Treatment includes antiseizure medications, surgery, and neurostimulation devices.
There are currently 2 epilepsy clinical trials recruiting participants in La Jolla, CA. These studies are seeking a combined 740 participants. Research is being sponsored by Biohaven Therapeutics Ltd., UCB Biopharma SRL. Clinical trial participation is free and participants receive study-related medical care at no cost.
Epilepsy Clinical Trials in La Jolla — FAQ
Are there epilepsy clinical trials in La Jolla?
Yes, there are 2 epilepsy clinical trials currently recruiting in La Jolla, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in La Jolla?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the La Jolla research site will contact you about next steps.
Are clinical trials in La Jolla free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many La Jolla studies also compensate for your time and travel.
What epilepsy treatments are being tested?
The 2 active trials in La Jolla are testing new therapies including novel drugs, biologics, and treatment approaches for epilepsy.
Data updated March 2, 2026 from ClinicalTrials.gov